Sarcoidosis is a systemic granulomatous disease including heart (cardiac sarcoidosis, CS). It has recently been reported that isolated CS, which presenting primarily cardiac symptoms without clinical evidence of sarcoid involvement in other organs. Diagnostic and prognostic biomarkers of CS, especially in isolated CS, have not yet been established.
S
arcoidosis is a systemic granulomatous disease of unknown origin that has variable clinical courses and affects multiple organs, including the heart (cardiac sarcoidosis, CS). 1) CS sometimes causes several complications, such as fatal ventricular arrhythmias, conduction block, congestive heart failure, and sudden cardiac death. 2, 3) The incidence of CS in sarcoidosis patients varies according to race and area. Cardiac involvement occurs only in 20-27% of sarcoidosis patients in the United States, whereas it may be as high as 58% in Japan.
2) It has recently been reported that isolated CS exists, presenting primarily as cardiac symptoms, conduction disturbances, ventricular arrhythmias, or left ventricular dysfunction, without clinical evidence of sarcoid involvement in other organs. 4, 5) One of the critical issues of isolated CS is that it is difficult to diagnose, since the existence of cardiac lesions should be detected from cardiac manifestations alone. 4, 5) Early detection of CS is important to improve the prognosis of sarcoidosis patients, and early induction of corticosteroids and other immunosuppressive agents is desirable for treatment. 6) Although myocardial biopsy is useful for diagnosing CS, this method is invasive and has low sensitivity. 2, 3) Other modalities, such as late gadolinium enhancement on magnetic resonance imaging or 18 Ffluorodeoxuglucose positron emission tomography (FDG PET), are helpful for diagnosing CS. 7) In addition, magnetic resonance imaging [8] [9] [10] and FDG PET 7, 8, 11, 12) are useful as markers of severity, as well as in the prognosis and judgement of treatment efficacy. These modalities are costly and repeated FDG PET exposes patients to ionizing radiation. Although a variety of cardiac imaging has demonstrated utility for diagnosing CS and predicting the prognosis of CS patients, a simple biomarker which we can measure repeatedly is needed.
Previous studies have reported that several biomarkers, such as angiotensin-converting enzymes (ACE), 13) soluble interleukin-2 receptors (sIL-2R), 14) B-type natriuretic peptides (BNP), 15, 16) and cardiac troponins 17, 18) are potentially useful in the diagnosis of CS and predicting progno-sis over the long term. However, a diagnostic and prognostic biomarker of CS has not yet been established. We hypothesize that each biomarker has different characteristics and a multiple biomarker approach supports comprehensive management of sarcoidosis patients. The aim of this study was to determine the utility of a multiple biomarker approach in CS patients.
Methods
Subjects and study protocol: This was a retrospective study. Sarcoidosis patients (n = 172) diagnosed between 2002 and 2015 were identified from their medical records. The diagnoses of sarcoidosis, 19) CS, [20] [21] [22] and isolated CS 4, 5) were made by the attending physician, based on several latest guidelines and statements. All sarcoidosis patients, who were diagnosed based on any organ, underwent screening for cardiac involvement as well as electrocardiography, echocardiography, computed tomography, and laboratory testing, and other advanced testing as needed (e.g.
67
gallium scintigraphy, 18 F-FDG PET, magnetic resonance imaging and myocardial biopsy). Additionally, in patients with heart failure and/or arrhythmia, 1) CS was defined based on several clinical findings including physical examination, echocardiography, 67 gallium scintigraphy, 18 F-FDG PET, computed tomography, magnetic resonance imaging and myocardial biopsy as needed, [20] [21] [22] and 2) CS patients without involvement of any other organs were defined as isolated CS after the above comprehensive examinations and assessments were performed. 4, 5) Echocardiography was performed blindly by experienced echocardiographers using standard techniques.
23) The left ventricular ejection fraction (LVEF) was calculated using Simpson's method. All measurements were performed using ultrasound systems (ACUSON Sequoia, Siemens Medical Solutions USA, Inc., Mountain View, CA, USA).
We compared several biomarkers (ACE, sIL-2R, BNP and troponin I) between non-cardiac sarcoidosis (non-CS, n = 123, 71.5%) and CS (n = 49, 28.5%), including nonisolated CS (n = 30, 17.4%) and isolated CS (n = 19, 11.1%). Non-CS involves sarcoid lesions of any organ other than the heart (lung, liver, kidney, skin, lymph node, nerve, eye, etc.). The status of all patients was obtained from their medical records for the occurrence of fatal arrhythmia and heart failure. Fatal arrhythmia was defined as ventricular fibrillation and/or sustained ventricular tachycardia documented by electrocardiograms or implantable devices, and heart failure was diagnosed by independent experienced cardiologists as the occurrence of heart failure in accordance with heart failure guidelines. 24, 25) Survival time was calculated from the date of sarcoidosis diagnosis until the date of death or last followup. The study protocol was approved by the Ethics Committee of Fukushima Medical University, and was carried out in accordance with the principles outlined in the Declaration of Helsinki. Reporting of the study conforms to STROBE along with references to STROBE and the broader EQUATOR guidelines.
26)
Measurement of laboratory data: Blood samples were obtained from all patients at Fukushima Medical University Hospital before steroid treatment. ACE and sIL-2R levels were quantitatively determined in serum with enzyme immunoassays according to the manufacturer's protocols (Insepack II-D, Kyokuto Seiyaku, Tokyo, Japan). BNP levels were measured using a specific immunoradiometric assay (Shionoria BNP kit, Shionogi, Osaka, Japan), and cardiac troponin I levels were measured in EDTA anticoagulated plasma using a refined assay (Abbott-Architect, Abbott Laboratories, Abbott Park, IL, USA). Statistical analysis: Normally distributed data are presented as the mean ± SD, and non-normally distributed data are presented as the median and interquartile range (i. e. sIL2R, BNP and troponin I). Categorical variables are expressed as numbers and percentages. The characteristics of the two groups were compared using Student's t-test, and the chi-square test was used for categorical variables. The prognostic value was tested by univariate and multivariate Cox proportional hazard analysis. To assess each biomarker's ability to predict CS in sarcoidosis patients, we estimated the area under the curve (AUC) of the receiver operating curve (ROC) to compare with other biomarkers using the DeLong test. A value of P < 0.05 was considered statistically significant for all comparisons. These analyses were performed using a statistical software package (SPSS ver. 24.0, IBM, Armonk, NY, USA).
Results
The clinical characteristics of the current study patients are presented in Table I . There were both non-CS (n = 123, 71.5%) and CS (n = 49, 28.5%) patients. The CS group included non-isolated CS patients (n = 30, 17.4%) and isolated CS patients (n = 19, 11.1%). Among the CS patients (n = 49), only 3 patients with non-isolated CS (6.1%) and 3 patients with isolated CS (6.1%) were diagnosed by endomyocardial biopsy. BNP levels were markedly higher in the CS group than in the non-CS group (278.5 versus 21.8 pg/mL, P < 0.001). In contrast, the ACE, sIL-2R, and cTnI levels did not differ between the two groups (Table I) . From the ROC analysis ( Figure) , BNP (a cut off value of 40 pg/mL) identified CS with a sensitivity of 85.4%, a specificity of 68.1%, and an area under the curve of 0.85 (95% CI 0.75-0.94, P < 0.01) in all sarcoidosis patients. The AUC of BNP to diagnose CS was superior to those of ACE, sIL-2R or troponin I (P ! 0.01, respectively).
In the CS patients (Table I) , the ACE and sIL-2R levels were significantly higher in non-isolated CS than in isolated CS (ACE, 25.8 versus 18.2 U/l, P = 0.041; sIL-2 R, 1170 versus 380.5 pg/mL, P = 0.038). In contrast, BNP and cTnI did not differ between the non-isolated CS and isolated CS groups (Table I) .
We also investigated the impact of these markers on the prognosis of CS patients. There were 13 events of fatal arrhythmia and 7 new onset heart failure events during the follow up period (mean 84 months). Cox proportional hazard analysis (Table II) revealed that only cTnI, but not ACE, IL2R or BNP, was a predictor of fatal arrhythmia after adjusting for LVEF, in the CS group (troponin I, hazard ratio 2.348, P = 0.006). In contrast, BNP, but not ACE, IL2R or troponin I, was a predictor of heart failure Kiko, ET AL
Figure.
Receiver operating curve (ROC) for identifying cardiac sarcoidosis in sarcoidosis patients (n = 172). AUC indicates area under the curve; CI, 95% confidence interval; and BNP, B-type natriuretic peptide. occurrence in the CS group, after adjusting for LVEF (BNP, hazard ratio 7.841, P = 0.008).
Discussion
The present study showed that higher ACE and sIL2-R are associated with systemic lesions, whereas BNP is a useful marker for detecting CS in sarcoidosis patients. In addition, troponin I is a predictor of fatal arrhythmia and BNP is a predictor of heart failure in CS patients. Thus, to the best of our knowledge, we are the first to report the utility of a multiple biomarker approach for comprehensive management of sarcoidosis.
MULTIPLE BIOMARKERS IN CARDIAC SARCOIDOSIS
In the current study, the diagnostic utility of BNP for detecting CS in sarcoidosis patients was more favorable than those of troponin I, ACE and sIL-2R, as shown by the ROC analysis. BNP has been widely used as a marker of left ventricular dysfunction and prognosis with heart failure. Concordant with our findings, it has been reported that natriuretic peptides are useful markers for identifying CS in sarcoidosis patients. 15, 16) In the present study, the cutoff value used for discrimination was 40 pg/mL for BNP, which is comparable to the values used in previous heart failure studies. 24, 25, 27) However, circulating BNP is affected by several factors, such as left ventricular hypertrophy, atrial fibrillation, older age and impaired renal function. 24, 25) Therefore, careful attention must be paid when considering a diagnosis of CS in the presence of such factors.
A notable result in the present study was that the plasma concentrations of ACE and sIL-2R in isolated CS were lower than those in non-isolated CS. Both ACE and sIL-2R are proposed markers of disease activity in sarcoidosis, and ACE levels have been reported to be elevated in 30-80% of sarcoidosis patients at the time of diagnosis. 13, 28) Circulating ACE is derived from activated macrophages and is useful in supporting a diagnosis and monitoring disease activity; however, the clinical value of ACE is controversial. 13) In addition, increased levels of sIL-2R have been found in the serum and bronchoalveolar lavage of lung sarcoidosis patients. One of the most characteristic immunologic features of the disease is the accumulation of activated CD4+ T-helper type 1 cells at disease sites, notably in the alveolar and interstitial spaces. 14) Although the specific role of sIL-2R in the immune response has not yet been fully described, elevated serum sIL-2R levels have been found to correlate with the activity of T-cellmediated diseases, and are for this reason considered to be a marker of T-cell activation. 14) In patients with systemic inflammation in multiple organs (non-isolated CS), the circulating sIL-2R is higher than those in isolated CS, which is restricted to inflammation on the myocardium. The present study suggested that only cardiac inflammation does not always make sIL-2R high in isolated CS. Therefore, we would like to emphasize that the possibility of isolated CS cannot be denied if the circulating levels of ACE and sIL-2R are not elevated.
The Cox proportional hazard analysis performed in the present study revealed that cTnI was useful for predicting fatal arrhythmia in the CS patients. Cardiac troponins are sensitive and specific markers of myocardial injury. 29, 30) Elevated circulating cardiac troponins associate with left ventricular dysfunction and may predict an adverse outcome, although further study is needed to verify this. 18) In addition, cardiac troponins in CS are suitable indicators of a favorable response to steroid therapy and are associated with prognosis. 17) Even a slight degree of myocyte damage can lead to many clinical complications which include fatal arrhythmia.
2) On the other hand, the present study showed that not cTnI but rather BNP predicts the occurrence of heart failure in CS patients. BNP has been recognized as a marker of left ventricular enddiastolic pressure and myocardial wall stress, 31, 32) and is associated with the occurrence of heart failure even in the general population.
33) The plasma level of cTnI was not associated with BNP in CS patients. 18) After steroid therapy, the cTnI concentration was normalized when the level of BNP remained high. 18) These observations indicate that cTnI seems to reflect ongoing myocyte injury in CS patients even when heart failure is not fully compensated. 18) Thus, elevated cTnI does not always predict heart failure. However, many primarily non-cardiac conditions may lead to increased circulating cardiac troponins. 29, 34) In advanced CS, it may be impossible to tell whether ele-vated concentrations are because of CS activity or the effects of cardiac and/or renal failure. 30) Further biomarkers in the diagnosis and prognosis of sarcoidosis are needed, and several biomarkers such as serum amyloid, tumor necrosis factor, tenascin-C, transforming growth factor-β1, and genome-wide gene expression signature strategies are potential candidates. 13) In addition, urinary 8-hydroxy-2'-deoxyguanosine has recently been reported to be a marker of inflammatory activity, and may be associated with cardiovascular mortality in CS patients even after steroid therapy. 35, 36) Study limitations: The current study has several limitations. First, as a retrospective study of a single center with a relatively small number of patients, diagnoses of sarcoidosis, CS and isolated CS were based on the decision of each attending physician, and the study may be somewhat underpowered. Although we conducted multivariable analyses to evaluate any associations between each biomarker and prognosis in CS patients, confounding factors cannot be entirely eliminated. However, CS is a relatively rare disease and the small study population was unavoidable; in addition, our study has a relatively larger study population than previous studies. [14] [15] [16] [17] [18] 28) Further studies with a prospective design and larger populations are needed to confirm our findings. Second, we did not have lysozyme data. Third, we did not consider any changes in parameters, and the baseline data at admission were used for the analyses.
Conclusions
Higher ACE and sIL2-R are associated with systemic lesions, whereas BNP is a useful marker with which to detect cardiac involvement in sarcoidosis patients. cTnI is a predictor of fatal arrhythmia and BNP is a predictor of heart failure in CS patients. Thus, a multiple biomarker approach supports comprehensive management of sarcoidosis.
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